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Background
Treatment of Chronic Idiopathic Urticaria (CIU) may
be challenging, as patients can be refractory to various
treatments. This may be due to an autoimmune mechan-
ism in its pathogenesis. CIU has been shown to be asso-
ciated with autoantibodies to IgE or IgE receptor and with
thyroid autoimmunity [1,2]. Treatments targeting this
autoimmune pathogenesis are now being used, such as
intravenous immunoglobulin (IVIG). We reviewed
patients with CIU treated with IVIG to see if response
to treatment correlated with presence of autoimmunity
(antibodies to IgE/IgE receptor or Thyroidperoxidase
(TPO) antibodies).
Methods
A retrospective chart review of patients seen in Allergy
and Clinical Immunology clinics at Health Sciences Centre
and Grace Hospital in Winnipeg was completed. Inclusion
criteria included treatment with IVIG with a clinical
diagnosis of CIU. There were a total of 21 patients
identified. 13 patients were treated with protocol A, 2g/kg
load split between 4 doses given within a two week period
followed by maintenance of 0.5 g/kg. Protocol B was
used for 8 patients consisting of monthly IVIG (60-80g).
Autoimmune blood work was recorded for Histamine
Release Assay (HRA) and TPO. HRA testing implies the
presence of antibodies to IgE or IgE receptor. Patients’
response to IVIG was recorded.
Results
HRA was done on 15 /21 patients and 5 of these patients
tested positive. 3/5 were able to maintain remission with
continued IVIG treatment, one relapsed after discontinu-
ing IVIG following remission and one was unresponsive to
IVIG. Anti-TPO was tested in 11 patients of which 3 were
positive. Of these three patients, one was responsive to
IVIG, one relapsed after initially being responsive and one
was unresponsive. Overall 13/21 patients were responsive
to IVIG. Of those who were responsive to IVIG 6 were
HRA negative and 3 HRA positive of the 9 tested, and
4 TPO negative and 1 TPO positive of the 5 tested
for TPO. When comparing protocols, 7/13 patients
who underwent protocol A responded without relapse
compared to 6/8 treated with protocol B.
Conclusion
IVIG can be effective in some patients with CIU who
are unresponsive to antihistamine treatment. A greater
number of patients who were responsive to IVIG had
negative results for the autoimmune tests we conducted.
Therefore, based on our data, the response to IVIG
cannot be determined by the presence of positive HRA
or TPO antibody.
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